UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2187-7
Program Prior Authorization/Medical Necessity
Medication Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei)*
P&T Approval Date 3/2020, 9/2020, 9/2021, 9/2022, 9/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background
Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] is a recombinant
coagulation Factor VIII concentrate indicated in adults and children with hemophilia A for:
On-demand treatment and control of bleeding episodes
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Perioperative management of bleeding
o
Esperoct is not indicated for the treatment of von Willebrand disease.
2. Coverage Criteriaa:
A. Initial Authorization:
1. Esperoct* will be initially approved based on the following criteria:
a. All of the following:
(1) Diagnosis of hemophilia A
-AND-
(2) One of the following:
(a) Submission of documentation showing failure to meet clinical goals (e.g.,
continuation of spontaneous bleeds, inability to achieve appropriate trough level)
after a trial of three of the following recombinant factor products:
1. Advate
2. Kogenate FS
3. Kovaltry
4. NovoEight
5. Nuwiq
6. Recombinate
-OR-
(b) Submission of documentation showing history of hypersensitivity to three of the
following recombinant factor products:
© 2025 UnitedHealthcare Services, Inc.
1
1. Advate
2. Kogenate FS
3. Kovaltry
4. NovoEight
5. Nuwiq
6. Recombinate
-OR-
(c) Prescriber attestation that patient would preferentially benefit from Esperoct
based on one of the following:
1. Patient is at high risk for the development of inhibitors (e.g., family history
of inhibitors and success with product, current treatment less than 50 days,
high risk genetic mutation, history of initial intensive therapy greater than 5
days)
2. Patient has developed inhibitors
3. Patient has undergone immune tolerance induction/ immune tolerance
therapy
-AND-
(3) One of the following:
(a) Patient is not to receive routine infusions more frequently than 2 times per week
-OR-
(b) Both of the following:
1. Patient is less than 12 years of age
-AND-
2. Pharmacokinetic (PK) testing results suggest that more frequent than 2 times
per week dosing is required
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Esperoct will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Esperoct therapy.
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
b. One of the following:
(1) Patient is not to receive routine infusions more frequently than 2 times per week
-OR-
(2) Both of the following:
(a) Patient is less than 12 years of age
-AND-
(b) PK testing results suggest that more frequent than 2 times per week dosing is
required
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
*Esperoct is typically excluded from coverage. Coverage reviews may be in place if required by law
or the benefit plan.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Esperoct® [package insert]. Plainsboro, NJ: CSL Novo Nordisk, Inc., July 2024.
2. Malec L, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis. In:
UpToDate, Waltham, MA, 2025.
3. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia
and Other Bleeding Disorders. MASAC Document #290, October 2, 2024.
Program Prior Authorization/Medical Necessity - Esperoct
Change Control
3/2020 New program.
9/2020 Modified program noting exclusion of coverage for majority of
benefits. Updated reference.
9/2021 Annual review with no changes to clinical criteria. Updated exclusion
statement with no change to clinical intent.
© 2025 UnitedHealthcare Services, Inc.
3
9/2022 Annual review. Added text “pharmacokinetic” to clarify abbreviation
“PK” with no changes to clinical intent. Updated background per
prescribing information and updated references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
3/2024 Annual review with no changes to clinical criteria.
3/2025 Annual review. Revised outline of coverage criteria without change to
clinical intent. Updated references.
© 2025 UnitedHealthcare Services, Inc.
4